Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOB Biotech GroupSHSE:688656 -2.73%83 Days Payable is 39.86 as of Mar. 2026, which is 15% above its 10-year median of 34.53. GuruFocus rates SHSE:688656 with a GF Score™ of 83/100 and a GF Value™ of ¥89.36 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 794 Medical Devices & Instruments companies, HOB Biotech Group ranks worse than 76.45% on this metric.
The historical rank and industry rank for HOB Biotech Group's Days Payable or its related term are showing as below:
SHSE:688656'
s Days Payable Range Over the Past 10 Years
Min: 19.38 Med: 34.53 Max: 91.85
Current: 39.38
During the past 10 years, HOB Biotech Group's highest Days Payable was 91.85. The lowest was 19.38. And the median was 34.53.
SHSE:688656's Days Payable is ranked worse than 76.45% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 67.85
vs SHSE:688656: 39.38
HOB Biotech Group's Days Payable
declined
from Mar. 2025 (96.58) to Mar. 2026 (39.86).
It may suggest that HOB Biotech Groupaccelerated paying its suppliers.
HOB Biotech Group Days Payable Related Terms
HOB Biotech Group Days Payable Historical Data
* Premium members only.
The historical data trend for HOB Biotech Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688656 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, HOB Biotech Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's Days Payable distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
HOB Biotech Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOB Biotech Group (SHSE:688656) has a Days Payable of 39.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HOB Biotech Group and its competitors. This is 15% above median its historical median of 34.53. Over the past decade, HOB Biotech Group's Days Payable has ranged from 19.38 to 91.85. According to the industry distribution chart, HOB Biotech Group ranks #607 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 76.4%.
Is HOB Biotech Group's Days Payable too high?
HOB Biotech Group's current Days Payable of 39.86 is 15% above median its 10-year median of 34.53. Over the past 10 years, this metric has ranged from a low of 19.38 to a high of 91.85. The Medical Devices & Instruments industry median Days Payable is 67.85. HOB Biotech Group's value of 39.86 is 41.3% below this industry median. Based on the distribution chart, HOB Biotech Group ranks #607 out of 794 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, HOB Biotech Group has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #607 out of 794 companies for Days Payable. This places HOB Biotech Group in the lower half of its industry. The industry median Days Payable is 67.85. HOB Biotech Group's value of 39.86 is 41.3% below this benchmark. Historically, HOB Biotech Group's own Days Payable has ranged from 19.38 to 91.85 over the past decade. While the company's 10-year median is 34.53 vs. the industry median of 67.85, HOB Biotech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.85, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current Days Payable of 39.86 is 41.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HOB Biotech Group and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current Days Payable is 39.86, which is 15% above median its own 10-year median of 34.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥89.36, compared to a current price of ¥79.04 — trading 11.5% below its estimated fair value. The current Days Payable is 39.86, which is 15% above median its 10-year median of 34.53 and 41.3% below the Medical Devices & Instruments industry median of 67.85. HOB Biotech Group's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current Days Payable is 39.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be undervalued.
The current stock price of ¥79.04 is trading 11.5% below its estimated GF Value™ of ¥89.36.
GuruFocus considers HOB Biotech Group to be Modestly Undervalued.
Key valuation signals for SHSE:688656:
Days Payable: 39.86 (15% above median its 10-year median of 34.53)
GF Value™: ¥89.36 vs. price of ¥79.04 (11.5% below fair value)
Industry Position: 41.3% below the Medical Devices & Instruments median (#607 of 794)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
83GF Score
Get the complete analysis for SHSE:688656
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
